| Id: | acc1923 |
| Group: | 2sens |
| Protein: | IGFBP-3 |
| Gene Symbol: | IGF2BP3 |
| Protein Id: | O00425 |
| Protein Name: | IF2B3_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser |
| Site Sequence: | |
| Disease Category: | Cancer |
| Disease: | Lung Cancer |
| Disease Subtype: | NSCLC |
| Disease Cellline: | H1299 |
| Disease Info: | |
| Drug: | Cisplatin |
| Drug Info: | "Cisplatin is a platinum-based chemotherapeutic agent widely used in the treatment of various malignancies, including ovarian, bladder, testicular, and non-small cell lung cancers, by forming DNA cross-links to interfere with replication and repair, thereby inhibiting cancer cell growth and proliferation." |
| Effect: | inhibit |
| Effect Info: | Phosphorylation of IGFBP - 3 by CK2 leads to enhanced resistance to cisplatin in human non - small cell lung cancer cell lines A549 and H1299. |
| Note: | site unclear |
| Score: | 5.0 |
| Pubmed(PMID): | 36766747 |
| Sentence Index: | 36766747_2-3 |
| Sentence: | "Much remains unknown regarding the basic operative mechanisms underlying cisplatin resistance in NSCLC. In this study, we found that phosphorylation of IGFBP-3 by CK2 (P-IGFBP-3) decreased its binding to hyaluronan (HA) but not to IGF-1 and rendered the protein less effective at reducing cell viability or increasing apoptosis than the non-phosphorylated protein with or without cisplatin in the human NSCLC cell lines, A549 and H1299." |
Sequence & Structure:
MNKLYIGNLSENAAPSDLESIFKDAKIPVSGPFLVKTGYAFVDCPDESWALKAIEALSGKIELHGKPIEVEHSVPKRQRIRKLQIRNIPPHLQWEVLDSLLVQYGVVESCEQVNTDSETAVVNVTYSSKDQARQALDKLNGFQLENFTLKVAYIPDEMAAQQNPLQQPRGRRGLGQRGSSRQGSPGSVSKQKPCDLPLRLLVPTQFVGAIIGKEGATIRNITKQTQSKIDVHRKENAGAAEKSITILSTPEGTSAACKSILEIMHKEAQDIKFTEEIPLKILAHNNFVGRLIGKEGRNLKKIEQDTDTKITISPLQELTLYNPERTITVKGNVETCAKAEEEIMKKIRESYENDIASMNLQAHLIPGLNLNALGLFPPTSGMPPPTSGPPSAMTPPYPQFEQSETETVHLFIPALSVGAIIGKQGQHIKQLSRFAGASIKIAPAEAPDAKVRMVIITGPPEAQFKAQGRIYGKIKEENFVSPKEEVKLEAHIRVPSFAAGRVIGKGGKTVNELQNLSSAEVVVPRDQTPDENDQVVVKITGHFYACQVAQRKIQEILTQVKQHQQQKALQSGPPQSRRK
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| IGF2BP3-Ser184 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -1.827 | ||||||||
| COAD | |||||||||
| HGSC | -0.205 | ||||||||
| ccRCC | 0.079 | ||||||||
| GBM | 1.408 | ||||||||
| HNSC | 0.649 | ||||||||
| LUAD | -1.425 | ||||||||
| LUSC | 0.638 | ||||||||
| non_ccRCC | 0.748 | ||||||||
| PDAC | 0.294 | ||||||||
| UCEC | -0.357 | ||||||||
| IGF2BP3-Ser187 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.707 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | -0.707 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| IGF2BP3-Ser496 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.848 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | -1.103 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.255 | ||||||||
| IGF2BP3-Thr528 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.321 |
| COAD | |
| HGSC | |
| ccRCC | -1.23 |
| GBM | |
| HNSC | -0.007 |
| LUAD | -0.568 |
| LUSC | -0.993 |
| non_ccRCC | |
| PDAC | 1.163 |
| UCEC | 1.313 |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PK | RPMI8226 | BTZ | 7.9942 | up | |
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PK | RPMI8226 | BTZ | 7.8395 | up | |
| O00425 | IGF2BP3 | P | Ser517 | TVNELQNLS(ph)SAEVVVPR | RPMI8226 | BTZ | 7.7627 | up | |
| O00425 | IGF2BP3 | P | Ser496 | VPS(ph)FAAGR | RPMI8226 | BTZ | 7.7311 | up | |
| O00425 | IGF2BP3 | P | Ser496 | VPS(ph)FAAGR | RPMI8226 | BTZ | 7.6984 | up | |
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PKEEVK | RPMI8226 | BTZ | 7.6908 | up | |
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PKEEVK | RPMI8226 | BTZ | 7.6323 | up | |
| O00425 | IGF2BP3 | P | Ser517 | TVNELQNLS(ph)SAEVVVPR | RPMI8226 | BTZ | 7.6019 | up | |
| O00425 | IGF2BP3 | P | Ser518 | TVNELQNLSS(ph)AEVVVPR | RPMI8226 | BTZ | 7.6015 | up | |
| O00425 | IGF2BP3 | P | Ser518 | TVNELQNLSS(ph)AEVVVPR | RPMI8226 | BTZ | 7.5364 | up | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 8.5168 | down | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 7.4524 | down | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Afatinib | 7.7894 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Afatinib | 8.3457 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Afatinib | 6.264 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Afatinib | 7.9987 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Dasatinib | 9.27 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Dasatinib | 10.7001 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Dasatinib | 8.3005 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Dasatinib | 8.2427 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Gefitinib | 9.3407 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Gefitinib | 7.1576 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Gefitinib | 9.0069 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Gefitinib | 8.7072 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A431 | Imatinib | 6.7244 | - | |
| O00425 | IGF2BP3 | P | Ser187 | QGSPGS(ph)VSK | A459 | MK2206 | 4.4584 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A459 | MK2206 | 7.6745 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A459 | Selumetinib | 7.3672 | - | |
| O00425 | IGF2BP3 | P | Ser180;Ser184 | GSS(ph)RQGS(ph)PGSVSK | A549 | AZD8055 | 7.2819 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | AZD8055 | 6.7524 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | Dactolisib | 7.296 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | Dasatinib | 8.276 | - | |
| O00425 | IGF2BP3 | P | Ser180;Ser184 | GSS(ph)RQGS(ph)PGSVSK | A549 | Dasatinib | 2 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | MK2206 | 10.0932 | - | |
| O00425 | IGF2BP3 | P | Ser180;Ser184 | GSS(ph)RQGS(ph)PGSVSK | A549 | MK2206 | 6.7348 | - | |
| O00425 | IGF2BP3 | P | Ser179;Ser184 | GS(ph)SRQGS(ph)PGSVSK | A549 | MK2206 | 2.0945 | - | |
| O00425 | IGF2BP3 | P | Ser180;Ser184 | GSS(ph)RQGS(ph)PGSVSK | A549 | Nintedanib | 8.5488 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | Nintedanib | 5.2592 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | PD325901 | 8.5472 | - | |
| O00425 | IGF2BP3 | P | Ser180;Ser184 | GSS(ph)RQGS(ph)PGSVSK | A549 | PD325901 | 8.5004 | - | |
| O00425 | IGF2BP3 | P | Ser180;Ser184 | GSS(ph)RQGS(ph)PGSVSK | A549 | PD325901 | 7.017 | - | |
| O00425 | IGF2BP3 | P | Ser179;Ser184 | GS(ph)SRQGS(ph)PGSVSK | A549 | PD325901 | 6.6602 | - | |
| O00425 | IGF2BP3 | P | Ser179;Ser184 | GS(ph)SRQGS(ph)PGSVSK | A549 | PD325901 | 6.467 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | PD325901 | 6.257 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | Pictilisib | 5.6232 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | Refametinib | 6.2374 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | A549 | Staursporin | 5.9547 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | 2.2794 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | -3.5423 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | -0.3022 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | 1.1305 | - | |
| O00425 | IGF2BP3 | P | Ser187 | QGSPGS(ph)VSK | ARH-77 | Rituximab | 0.9421 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | -1.2389 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | 0.9652 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | 2.4692 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | ARH-77 | Rituximab | 2.0458 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | HeLa | A485 | 10.539 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | HeLa | A486 | 14 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | HeLa | CUDC101 | 8.2979 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | HeLa | Curcumin | 5.6065 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | HeLa | SAHA | 8.3479 | - | |
| O00425 | IGF2BP3 | P | Ser180;Ser184 | GSS(ph)RQGS(ph)PGSVSK | K562 | Cytarabine | 6.7557 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Cytarabine | 4.9331 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Dasatinib | 11.384 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Dasatinib | 9.0268 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Dasatinib | 9.005 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Dasatinib | 9.7553 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Dasatinib | 9.6881 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Dasatinib | 9.7677 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Dasatinib | 7.259 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | K562 | Imatinib | 9.4268 | - | |
| O00425 | IGF2BP3 | P | Ser184;Ser187 | QGS(ph)PGS(ph)VSK | K562 | Imatinib | 9.2635 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | KYSE-520 | SHP099 | 6.2559 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | PC-9 | AZD4547 | 8.3749 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | PC-9 | Gefitinib | 6.5434 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | PC-9 | GeftinibAZD4547-1to80 | 6.3489 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | PC-9 | Lapatinib | 7.297 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | PC-9 | LapatinibAZD4547 | 8.4984 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | Ramos | Rituximab | -4.0441 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | Ramos | Rituximab | -0.8513 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | Ramos | Rituximab | 2.2151 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | Ramos | Rituximab | -1.7381 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | Ramos | Rituximab | -2.7558 | - | |
| O00425 | IGF2BP3 | P | Ser179;Ser184 | GS(ph)SRQGS(ph)PGSVSK | RPMI8226 | BTZ | 10.2715 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 9.506 | - | |
| O00425 | IGF2BP3 | P | Ser179;Ser184 | GS(ph)SRQGS(ph)PGSVSK | RPMI8226 | BTZ | 9.4823 | - | |
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PK | RPMI8226 | BTZ | 8.3445 | - | |
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PK | RPMI8226 | BTZ | 7.5974 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 4.8091 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 8.2777 | - | |
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PK | RPMI8226 | BTZ | 8.2537 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 8.1644 | - | |
| O00425 | IGF2BP3 | P | Ser481 | IKEENFVS(ph)PK | RPMI8226 | BTZ | 7.8669 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 8.0595 | - | |
| O00425 | IGF2BP3 | P | Ser517 | TVNELQNLS(ph)SAEVVVPR | RPMI8226 | BTZ | 7.8157 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 7.5665 | - | |
| O00425 | IGF2BP3 | P | Ser517 | TVNELQNLS(ph)SAEVVVPR | RPMI8226 | BTZ | 6.6189 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 8.3678 | - | |
| O00425 | IGF2BP3 | P | Ser517 | TVNELQNLS(ph)SAEVVVPR | RPMI8226 | BTZ | 7.6563 | - | |
| O00425 | IGF2BP3 | P | Ser517 | TVNELQNLS(ph)SAEVVVPR | RPMI8226 | BTZ | 7.4518 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | RPMI8226 | BTZ | 6.8969 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | SU-DHL-4 | Rituximab | -1.3954 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | SU-DHL-4 | Rituximab | -1.2706 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | SU-DHL-4 | Rituximab | 0.9864 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | SU-DHL-4 | Rituximab | -1.4366 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | SU-DHL-4 | Rituximab | -0.5032 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | SU-DHL-4 | Rituximab | -1.4469 | - | |
| O00425 | IGF2BP3 | P | Ser187 | QGSPGS(ph)VSK | SU-DHL-4 | Rituximab | -1.3056 | - | |
| O00425 | IGF2BP3 | P | Ser184 | QGS(ph)PGSVSK | SU-DHL-4 | Rituximab | -1.1865 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
